Fintel reports that on September 29, 2025, B. Riley Securities maintained coverage of Madrigal Pharmaceuticals (NasdaqGS:MDGL ...

Discover why MDGL's Rezdiffra leads in MASH therapy with rapid US and EU expansion. Learn about growth potential and risks.

In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and bearish perspectives.

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

B. Riley raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $560 from $460 and keeps a Buy rating on the shares following a ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

HC Wainwright initiated coverage on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) in a report released on Thursday, Marketbeat reports. The brokerage issued a buy rating and a $500.00 ...

CONSHOHOCKEN, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...

Analysts' ratings for Madrigal Pharmaceuticals (NASDAQ:MDGL) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below offers a condensed view of their recent ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the most shorted stocks right now. On August 25, TD Cowen analyst Ritu Baral raised her price target on Madrigal Pharmaceuticals (NASDAQ:MDGL) to ...

While only two therapies have so far gained approval, the broader pipeline paints a picture of strong research and ...